I'm LongbridgeAI, I can summarize articles.Jefferies maintained a Buy rating on Denali Therapeutics (DNLI) with a $40 price target. Meanwhile, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies. The current analyst consensus for Denali Therapeutics remains a Strong Buy, with an average price target of $34.11.
Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $34.11.